Centurium Capital is a leading private equity investment firm in China with a primary focus on China's consumer, business services, healthcare and technology sectors.
Taibang Biologic Group Secures Equity Raising of US$300 MillionTaibang Biologic Group (previously listed as China Biologic Products Holdings, Inc. on the Nasdaq under the trading symbol “CBPO”) (the “Group”) entered into definitive transaction documents for equity raising of US$300 million with a group of investors led by Platinum Orchid, a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), and GIC. China Life...MORE
Centurium Capital Leads Investment in NTX™ in Latest US$200 Million C2 RoundShanghai/Singapore, August 1, 2022 -- NTX™, a global textile technology leader, announced today the completion of nearly US$200 million in a C2 round of financing led by Centurium Capital, with additional contributions from existing shareholder NRL Capital. The funds will be used to accelerate growth and fund operational needs to meet the rapidly rising demand...MORE
Centurium Capital Advances Significantly in the Latest PEI 300 RankingJune 8, 2022, Beijing – Centurium Capital was ranked 139th place in the latest 2022 PEI 300 ranking, advancing over 100 places compared with the previous year’s ranking, as released recently by Private Equity International. The ranking marks the total size of funds raised in the last five years as of March 31, 2022 and...MORE
ANE Releases 2021 ESG ReportJune 6, 2022, Shanghai -- ANE Inc. (9956.HK), a portfolio company of Centurium Capital and a leading less-than-truckload (LTL) logistics service provider in China, released its 2021 ESG Report on May 31, highlighting its ESG commitments and efforts in green operation, efficiency improvement, supply chain management and employment management in 2021. Jeff Wang, Chairman of...MORE